Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oleg Gluz

Showing results (31-40 of 97) with videos related to

Pageof 10
Sort By:
Molecular Oncology|April 14, 2023
Prognostic and predictive impact of gene expression in node-positive early breast cancer patients receiving dose-dense versus standard-dose adjuvant chemotherapyMattea Reinisch, Simona Bruzas, Oleg Gluz, et al.
Science Translational Medicine|November 27, 2015
Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockadePhilipp Müller, Matthias Kreuzaler, Tarik Khan, et al.
Breast Cancer Research : BCR|May 16, 2020
Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)-a translational analysis of the prospective WSG PlanB trialCornelia Kolberg-Liedtke, Oleg Gluz, Fred Heinisch, et al.
Molecular Cancer Research : MCR|January 5, 2020
Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1Vineesh Indira Chandran, Ann-Sofie Månsson, Magdalena Barbachowska, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2007
Protein expression profiling in high-risk breast cancer patients treated with high-dose or conventional dose-dense chemotherapyRaihanatou Diallo-Danebrock, Evelyn Ting, Oleg Gluz, et al.
NPJ Breast Cancer|March 30, 2022
Gene signatures in patients with early breast cancer and relapse despite pathologic complete responseSimona Bruzas, Oleg Gluz, Nadia Harbeck, et al.
Cancer Treatment Reviews|October 20, 2023
Favorable impact of therapy management by an interactive eHealth system on severe adverse events in patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer treated by palbociclib and endocrine therapyNadia Harbeck, Ronald Kates, Timo Schinköthe, et al.
International Journal of Cancer|March 7, 2016
BRCA1-like profile predicts benefit of tandem high dose epirubicin-cyclophospamide-thiotepa in high risk breast cancer patients randomized in the WSG-AM01 trialPhilip C Schouten, Oleg Gluz, Nadia Harbeck, et al.
Breast Care (Basel, Switzerland)|November 1, 2021
Phenotype Discordance between Primary Tumor and Metastasis Impacts Metastasis Site and Outcome: Results of WSG-DETECT-PriMetCornelia Kolberg-Liedtke, Rachel Wuerstlein, Oleg Gluz, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|March 6, 2025
Clinicopathological Characteristics of a Distinct Tumor Phenotype: Invasive Lobular Carcinoma With Tubular Elements in the West German Study Group ADAPTcycle TrialMartin Radner, Sandy Burmeister, Katarzyna Jóźwiak, et al.
Pageof 10

Showing results (31-40 of 97) with videos related to

Sort By:
Pageof 10
Molecular Oncology|April 14, 2023
Prognostic and predictive impact of gene expression in node-positive early breast cancer patients receiving dose-dense versus standard-dose adjuvant chemotherapyMattea Reinisch, Simona Bruzas, Oleg Gluz, et al.
Science Translational Medicine|November 27, 2015
Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockadePhilipp Müller, Matthias Kreuzaler, Tarik Khan, et al.
Breast Cancer Research : BCR|May 16, 2020
Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)-a translational analysis of the prospective WSG PlanB trialCornelia Kolberg-Liedtke, Oleg Gluz, Fred Heinisch, et al.
Molecular Cancer Research : MCR|January 5, 2020
Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1Vineesh Indira Chandran, Ann-Sofie Månsson, Magdalena Barbachowska, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2007
Protein expression profiling in high-risk breast cancer patients treated with high-dose or conventional dose-dense chemotherapyRaihanatou Diallo-Danebrock, Evelyn Ting, Oleg Gluz, et al.
NPJ Breast Cancer|March 30, 2022
Gene signatures in patients with early breast cancer and relapse despite pathologic complete responseSimona Bruzas, Oleg Gluz, Nadia Harbeck, et al.
Cancer Treatment Reviews|October 20, 2023
Favorable impact of therapy management by an interactive eHealth system on severe adverse events in patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer treated by palbociclib and endocrine therapyNadia Harbeck, Ronald Kates, Timo Schinköthe, et al.
International Journal of Cancer|March 7, 2016
BRCA1-like profile predicts benefit of tandem high dose epirubicin-cyclophospamide-thiotepa in high risk breast cancer patients randomized in the WSG-AM01 trialPhilip C Schouten, Oleg Gluz, Nadia Harbeck, et al.
Breast Care (Basel, Switzerland)|November 1, 2021
Phenotype Discordance between Primary Tumor and Metastasis Impacts Metastasis Site and Outcome: Results of WSG-DETECT-PriMetCornelia Kolberg-Liedtke, Rachel Wuerstlein, Oleg Gluz, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|March 6, 2025
Clinicopathological Characteristics of a Distinct Tumor Phenotype: Invasive Lobular Carcinoma With Tubular Elements in the West German Study Group ADAPTcycle TrialMartin Radner, Sandy Burmeister, Katarzyna Jóźwiak, et al.
Pageof 10